New Protocol: Pembrolizumab with Chemotherapy in Advanced Endometrial Cancer
Study
Phase III, randomized, double-blind, placebo-controlled
|
Advanced-stage, metastatic, or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma
|
Pembrolizumab + Chemotherapy (n=365) vs. Chemotherapy (n=548)
|
|
Efficacy
dMMR cohort
|
mPFS: NR vs. 7.6 mos, p<0.001
|
12 mos PFS: 74% vs. 38%, p<0.001
|
|
pMMR cohort
|
mPFS: 13.1 vs. 8.7 mos, p<0.001
|
Safety
Any grade: fatigue (71.6% vs 55.7%), peripheral sensory neuropathy (65% vs.62%), anemia (57.8% vs. 54.7%), nausea (50.5% vs. 41.5%)
|
|
Grade≥3 AEs: Anemia (19.3% vs. 10.4%), neutropenia (11.9% vs. 17.0%)
|
|
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023
